Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.35 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30320724 | 1.00 | MME (0.35) | MMECTRB1ACESLC15A2 | |
| SCHEMBL30724654 | 0.99 | MME (0.36) | MMECTRB1ACE | |
| SCHEMBL30781078 | 0.99 | MME (0.36) | MMECTRB1ACE | |
| SCHEMBL30781160 | 0.99 | MME (0.36) | MMECTRB1ACE | |
| SCHEMBL30781156 | 0.96 | MME (0.39) | MMECTRB1SLC15A2 | |
| SCHEMBL31113634 | 0.95 | CTRB1 (0.36) | MMECTRB1ACESLC15A2 | |
| SCHEMBL3916119 | 0.93 | CTRB1 (0.37) | MMECTRB1ACE | |
| SCHEMBL749822 | 0.93 | CTRB1 (0.37) | MMECTRB1ACE | |
| SCHEMBL3810013 | 0.93 | CTRB1 (0.37) | MMECTRB1ACE | |
| SCHEMBL17293240 | 0.93 | CTRB1 (0.37) | MMECTRB1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023085418-A1 | FUSION PROTEIN OF VIRUS-INHIBITING MOLECULE AND STREPTAVIDIN VARIANT | 国立大学法人 東京大学 | 2023-05-19 | — | — | WO | claimed |
| US-12540188-B2 | IL10Rα/IL2Rγ synthetic cytokines | SYNTHEKINE, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250376528-A1 | COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS | SYNTHEKINE INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250340656-A1 | COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS | SYNTHEKINE INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333520-A1 | COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING | SYNTHEKINE INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250163162-A1 | COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRING | SYNTHEKINE, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12291572-B2 | IL12 receptor synthetic cytokines and methods of use | SYNTHEKINE, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250019453-A1 | IL2RB/IL2G SYNTHETIC CYTOKINES | SYNTHEKINE, INC. | 2025-01-16 | — | — | US | disclosed |
| US-12122839-B2 | IFNGR binding synthetic cytokines and methods of use | SYNTHEKINE, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240026014-A1 | COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS | SYNTHEKINE INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230279126-A1 | IL23 RECEPTOR SYNTHETIC CYTOKINES AND METHODS OF USE | SYNTHEKINE, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230272088-A1 | IFNGR BINDING SYNTHETIC CYTOKINES AND METHODS OF USE | SYNTHEKINE, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230272095-A1 | IL10Ra/IL2Ry SYNTHETIC CYTOKINES | INC., SYNTHEKINE | 2023-08-31 | — | — | US | disclosed |
| US-20230272094-A1 | IL2RB/IL2RG SYNTHETIC CYTOKINES | SYNTHEKINE, INC. | 2023-08-31 | — | — | US | disclosed |
| EP-4200339-A2 | COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS | Synthekine, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-4192877-A1 | IL2RB/IL2RG SYNTHETIC CYTOKINES | Synthekine, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022150788-A2 | COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRING | SYNTHEKINE, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150791-A2 | COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING | SYNTHEKINE, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022055641-A2 | COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS | SYNTHEKINE, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022032037-A1 | IL23 RECEPTOR SYNTHETIC CYTOKINES AND METHODS OF USE | SYNTHEKINE, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540188-B2 | IL10Rα/IL2Rγ synthetic cytokines | IL2, IL2RA, IL23R | MME 4103/4885CTRB1 2234/4885ACE 4785/4885 |
| US-20250333520-A1 | COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING | IL2RA, IL23R, IL2 | MME 2050/4885CTRB1 3016/4885ACE 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.